These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35071135)

  • 21. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.
    Méaux MN; Sellier-Leclerc AL; Acquaviva-Bourdain C; Harambat J; Allard L; Bacchetta J
    Pediatr Nephrol; 2022 Apr; 37(4):907-911. PubMed ID: 35015123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside.
    D'Ambrosio V; Ferraro PM
    Int J Nephrol Renovasc Dis; 2022; 15():197-206. PubMed ID: 35747094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrocalcinosis can disappear in infants receiving early lumasiran therapy.
    Kayal D; Sellier-Leclerc AL; Acquaviva-Bourdain C; de Mul A; Cabet S; Bacchetta J
    Pediatr Nephrol; 2024 Jul; 39(7):2079-2082. PubMed ID: 38261066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
    Forbes TA; Brown BD; Lai C
    Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lumasiran: First Approval.
    Scott LJ; Keam SJ
    Drugs; 2021 Feb; 81(2):277-282. PubMed ID: 33405070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
    Bollée G; Cochat P; Daudon M
    Can J Kidney Health Dis; 2015; 2():31. PubMed ID: 26380104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?
    Pozdzik A; David C; Vekeman J; Tielens F; Daudon M
    IJU Case Rep; 2021 Jul; 4(4):235-238. PubMed ID: 34258537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving Treatment Options for Primary Hyperoxaluria.
    Hoppe B; Martin-Higueras C
    Drugs; 2022 Jul; 82(10):1077-1094. PubMed ID: 35779234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of Primary Hyperoxaluria Type 1 in Italy].
    Ferraro PM; Gambaro G; Mandrile G; Montini G; Pasini A; Peruzzi L
    G Ital Nefrol; 2021 Apr; 38(2):. PubMed ID: 33852222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
    Biebuyck N; Destombes C; Prakash R; Boyer O
    J Nephrol; 2023 Jun; 36(5):1473-1476. PubMed ID: 37209362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinguishing characteristics of pediatric patients with primary hyperoxaluria type 1 in PEDSnet.
    Tasian GE; Dickinson K; Park G; Marchesani N; Mittal A; Cheng N; Ching CB; Chu DI; Walton R; Yonekawa K; Gluck C; Muneeruddin S; Kan KM; DeFoor W; Rove K; Forrest CB
    J Pediatr Urol; 2024 Feb; 20(1):88.e1-88.e9. PubMed ID: 37848358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1.
    Zheng R; Fang X; Chen X; Huang Y; Xu G; He L; Li Y; Niu X; Yang L; Wang L; Li D; Geng H
    Clin Transl Med; 2020 Dec; 10(8):e261. PubMed ID: 33377632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.
    Sawyer K; Leahy S; Wood KD
    BioDrugs; 2022 Jul; 36(4):437-441. PubMed ID: 35731461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: A case report.
    Villani V; Gupta N; Elias N; Vagefi PA; Markmann JF; Paul E; Traum AZ; Yeh H
    Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28261895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3.
    Groothoff J; Sellier-Leclerc AL; Deesker L; Bacchetta J; Schalk G; Tönshoff B; Lipkin G; Lemoine S; Bowman T; Zhou J; Hoppe B
    Kidney Int Rep; 2024 May; 9(5):1387-1396. PubMed ID: 38707801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
    Baum MA; Langman C; Cochat P; Lieske JC; Moochhala SH; Hamamoto S; Satoh H; Mourani C; Ariceta G; Torres A; Wolley M; Belostotsky V; Forbes TA; Groothoff J; Hayes W; Tönshoff B; Takayama T; Rosskamp R; Russell K; Zhou J; Amrite A; Hoppe B;
    Kidney Int; 2023 Jan; 103(1):207-217. PubMed ID: 36007597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut microbiota and oxalate homeostasis.
    Hatch M
    Ann Transl Med; 2017 Jan; 5(2):36. PubMed ID: 28217701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria.
    Marangella M; Cosseddu D; Petrarulo M; Vitale C; Linari F
    Nephrol Dial Transplant; 1993; 8(12):1333-7. PubMed ID: 8159301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.